Clearmind Medicine Inc. Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019
Clearmind Medicine Inc. (CMND) reported Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 of 442.22 CAD/shares for the 12-month period ending 2023-10-31, per its 20-F filed 2025-01-22.
Financial Statements › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 · last filed 2025-01-22
CAD/shares
| Period end | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 6 month | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 12 month | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 12 month as first filed |
|---|---|---|---|
| 2023-10-31 | 442.22 CAD/shares 20-F · filed 2025-01-22 | ||
| 2023-04-30 | 1.67 CAD/shares 6-K · filed 2023-06-14 | ||
| 2022-10-31 | 10.55 CAD/shares 6-K · filed 2023-06-14 | 10.57 CAD/shares 20-F · filed 2023-02-06 | |
| 2021-10-31 | 23.10 CAD/shares 20-F · filed 2023-02-06 |
USD/shares
| Period end | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 3 month | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 6 month | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 12 month | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 12 month as first filed |
|---|---|---|---|---|
| 2023-10-31 | $318.81 20-F · filed 2025-01-22 | |||
| 2023-04-30 | $1.23 6-K · filed 2023-06-14 | |||
| 2023-01-31 | $5.01 6-K · filed 2023-03-17 | |||
| 2022-10-31 | $455.71 20-F/A · filed 2024-03-18 | $10.55 6-K · filed 2023-03-17 |